Gastric Cancer is a leading journal in the field of oncology, published by SPRINGER in Japan. With an ISSN of 1436-3291 and an E-ISSN of 1436-3305, this esteemed journal aims to disseminate high-quality research focused on all aspects of gastric cancer, including its pathophysiology, diagnosis, treatment, and prevention. As an indicator of its academic excellence, Gastric Cancer is ranked in the top quartile (Q1) for Cancer Research, Gastroenterology, Medicine (miscellaneous), and Oncology categories as of 2023. The journal holds impressive Scopus rankings, being positioned #9 in Gastroenterology and #34 in Oncology, demonstrating its critical role in shaping advancements within these disciplines. Although not an open-access publication, it provides various access options for institutions and individuals looking to elevate their understanding of gastric cancer. With a converged publication history from 2000 to 2024, it serves as a vital resource for researchers, professionals, and students dedicated to eradicating this formidable disease.

Cancer Medicine is a leading open access journal published by WILEY, focusing on innovative research and advancements in the fields of Cancer Research, Oncology, and Radiology, with an impressive impact evidenced by its 2023 Q2 ranking in Cancer Research and Q1 rankings in both Oncology and Radiology, Nuclear Medicine and Imaging. With an ISSN of 2045-7634, this journal has been committed to disseminating pivotal findings since its inception in 2012, serving as a vital platform for researchers, practitioners, and students alike. The journal proudly embodies the spirit of open access, ensuring that groundbreaking cancer research is accessible to a global audience. Located in the United Kingdom, it spans a wide array of topics, promising comprehensive insights into cancer therapies, molecular mechanisms, and imaging techniques, thereby significantly contributing to the enhancement of cancer care and treatment outcomes. Researchers interested in exploring the latest advancements in cancer medicine will find this journal an indispensable resource.

JNCI-Journal of the National Cancer Institute, published by Oxford University Press Inc. in the United Kingdom, is a premier journal dedicated to advancing the field of cancer research and oncology. With a distinguished history dating back to 1940, this journal has consistently maintained a strong reputation within the academic community, achieving a remarkable Q1 ranking in both Cancer Research and Oncology as of 2023. Researchers and practitioners rely on the JNCI for original research articles, review papers, and cutting-edge findings that impact clinical practices and therapeutic strategies. Although it does not currently offer open access, the journal remains a vital resource for academicians and healthcare professionals seeking to enhance their understanding of cancer mechanisms and treatment innovations. Its rigorous peer-review process ensures the publication of high-quality, credible research that meets the evolving challenges of cancer treatment and prevention through to 2024.

Journal of the Egyptian National Cancer Institute, published by SPRINGER, serves as a vital platform for disseminating innovative research in the field of oncology and cancer research. With both ISSN 1110-0362 and E-ISSN 2589-0409, this Open Access journal has been committed to making significant contributions to the scientific community since its inception in 2005. Operating from its base in Egypt, it has established itself as an important resource for researchers, practitioners, and students alike, offering insights into contemporary issues and advancements in cancer care. Recognized in the 2023 category quartiles as Q3 in Cancer Research and Q3 in Oncology, the journal is positioned to impact the ongoing discourse in cancer treatment strategies and health policy. As it continues to publish peer-reviewed articles through available Open Access avenues, the Journal of the Egyptian National Cancer Institute remains dedicated to enhancing the knowledge base and collaborative efforts within the global cancer research community.

The International Journal of Breast Cancer is a premier academic platform dedicated to advancing the field of breast cancer research and treatment. Published by HINDAWI LTD, this journal embraces an Open Access model since 2011, ensuring that cutting-edge research is readily accessible to all, facilitating the dissemination of knowledge across the global scientific community. With its ISSN 2090-3170 and E-ISSN 2090-3189, the journal caters to a diverse audience comprising researchers, clinicians, and students engaged in oncology and pharmacology. The journal has consistently demonstrated its relevance, classified in the Q4 quartile for Cancer Research and the Q3 quartile for both Oncology and Pharmacology in the latest rankings. It currently ranks #151/272 in the Medicine & Pharmacology category and #232/404 in Medicine & Oncology according to Scopus, showcasing its adaptive role in an evolving field. Commencing in 2013 and continuing through to 2024, the journal is positioned to be an essential resource, addressing critical topics and fostering innovative solutions for breast cancer challenges.

Breast Cancer Management is a pivotal journal in the field of oncology and radiology, published by FUTURE MEDICINE LTD. Since its transition to Open Access in 2018, the journal has aimed to democratize access to cutting-edge research focused on innovative treatments and management strategies for breast cancer. With an ISSN of 1758-1923 and an E-ISSN of 1758-1931, it provides a platform for researchers and clinicians to share findings that enhance patient care and outcomes. The journal has garnered significant attention, placing in the Q3 quartile in Oncology and Q2 in Radiology, Nuclear Medicine, and Imaging as of 2023. Positioned in the United Kingdom, its editorial focus and rigorous peer-review process ensure that it remains at the forefront of breast cancer research. As breast cancer continues to be a major health concern globally, Breast Cancer Management serves as an essential resource for advancing knowledge and fostering collaboration among professionals in this vital area of medicine.

The Breast Journal, published by Wiley-Hindawi, is a distinguished Open Access journal dedicated to the fields of internal medicine, oncology, and surgery with a particular focus on breast health and disease. Since its inception in 1995, the journal has become an essential resource for researchers and clinicians, facilitating the dissemination of high-quality research and innovative clinical practices. With an impact factor reflecting robust scholarly influence and a ranking in the Q3 quartile for both internal medicine and oncology, as well as Q2 in surgery, it showcases significant contributions that advance knowledge and improve patient outcomes. Offering unparalleled access to its articles, The Breast Journal aims to support a global audience in exploring the multifaceted challenges and breakthroughs in breast-related health, making it a vital platform for shared learning and scientific discourse.

South Asian Journal of Cancer, published by GEORG THIEME VERLAG KG, is a pivotal platform for research in the fields of oncology and cancer research. Established in 2012 and operating under an Open Access model, this journal aims to disseminate high-quality, peer-reviewed articles that address crucial developments in cancer treatment, prevention, and research, particularly within the South Asian context. Despite its young history, the journal has been positioned within the Q4 quartile for both Cancer Research and Oncology, and while current Scopus rankings indicate it resides in the lower percentiles, its commitment to amplifying regional voices and research is invaluable. With its headquarters in Stuttgart, Germany, and a global readership, South Asian Journal of Cancer is dedicated to enhancing collaboration among researchers, healthcare professionals, and students, fostering a space for innovative ideas and advancements in cancer care as we progress through to 2024.

Current Breast Cancer Reports is a vital academic journal published by Springer that focuses on the latest research and advancements in the field of breast cancer. With its ISSN 1943-4588 and E-ISSN 1943-4596, this journal serves as an essential resource for oncologists, researchers, and healthcare professionals dedicated to improving diagnosis and treatment strategies for breast cancer. Spanning from 2009 to 2024, it provides a platform for high-quality, peer-reviewed articles that encompass a range of topics, including molecular biology, clinical trials, and innovative therapeutic approaches. Although it is currently classified in the Q3 category in Oncology and is positioned in the 29th percentile, the journal remains committed to elevating its academic impact and contributing meaningfully to the ongoing fight against breast cancer. As it seeks to disseminate critical findings and foster collaboration within the scientific community, Current Breast Cancer Reports is poised to be an indispensable tool for anyone keen on advancing the field.

ONCOLOGY is a prestigious journal published by KARGER, dedicated to advancing the field of cancer research and treatment. Established in 1948, this peer-reviewed journal has established a significant presence in the medical community, reflected by its impressive impact factor and Q2 category rankings in both Cancer Research and Oncology as of 2023. With a focus on groundbreaking research and comprehensive reviews, ONCOLOGY serves as a crucial resource for researchers, clinicians, and students interested in the latest developments in the fight against cancer. Although it currently does not offer open access, the journal's reputation ensures that it reaches a wide audience in academia and clinical practice. Its commitment to excellence is underscored by its consistent rankings in key disciplines, making it a vital publication for anyone involved in cancer research, biology, or associated medical fields. The journal is headquartered in Basel, Switzerland, positioning it at the heart of European medical research.